AFP - L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)
Patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolisation
are enrolled in this clinical trial. The aim of this trial is to evaluate the usefulness of
the liver cancer markers AFP, AFP-L3% (subfraction of AFP) and des-y- carboxyprothrombin
(DCP) after TACE therapy. Some authors could have shown that AFP-L3% is rising in small
tumor nodules under 2 cm and so the markers which should decrease after TACE can give a hint
for the therapeutic response after the intervention. So the important aim of this trial is
to improve the early detection of tumor recurrence after TACE.
Furthermore the quality of life measured by the EORTC QLQ C30 before and after TACE is
Observational Model: Cohort, Time Perspective: Prospective
comparison of liver cancer markers AFP, AFP-L3% and DCP before and after TACE
Liver cancer markers AFP, AFP-L3 and DCP are measured before TACE, 1 month and 3 months after TACE in order to evaluate the course of these markers after the intervention
baseline, 1 month and 3 months
Hans Christian Spangenberg, Prof. Dr.
University Medical Center Freiburg
Germany: Ethics Commission